Xeligekimab injection

DRUG3 trials

Sponsors

Chongqing Genrix Biopharmaceutical Co., Ltd, Lingli Dong, First Hospital of China Medical University

Conditions

Genital PsoriasisNail PsoriasisNon-Radiographical Axial SpondyloarthritisNr-axial SpondyloarthritisPalmoplantar PsoriasisPalmoplantar Pustulosis (PPP)Plaque PsoriasisPsoriatic Arthritis

Phase 2

Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis

Not yet recruitingNCT07339566

Lingli DongNon-Radiographical Axial Spondyloarthritis, Nr-axial Spondyloarthritis

Start: 2026-01-31End: 2028-01-30Target: 40Updated: 2026-01-14

Phase 4

Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis

RecruitingNCT07503652

First Hospital of China Medical UniversityPalmoplantar Pustulosis (PPP)

Start: 2026-03-01End: 2027-12-01Target: 10Updated: 2026-03-31

Unknown Phase

Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)

Not yet recruitingNCT06802848

Chongqing Genrix Biopharmaceutical Co., LtdGenital Psoriasis, Nail Psoriasis, Palmoplantar Psoriasis +3

Start: 2025-01-30End: 2026-12-31Target: 1000Updated: 2025-01-31